Search

1. Mepolizumab (Nucala®, GlaxoSmithKline plc.) for the treatment of severe asthma with eosinophilia: effectiveness, value, and value-based price benchmarks : final report

Author(s):

Tice, Jeffrey A., author
Ollendorf, Daniel A., author
Campbell, Jonathan D., author
Chapman, Rick M., author
Shore, Karen K., author
Weissberg, Jed, author
Whittington, Melanie, author
Pearson, Steven D., author

Publication:

[Boston, MA] : Institute for Clinical and Economic Review, March 14, 2016

Subject(s):

Adrenergic beta-2 Receptor Agonists -- economics
Adrenergic beta-2 Receptor Agonists -- therapeutic use
Anti-Asthmatic Agents -- administration & dosage
Anti-Asthmatic Agents -- economics
Antibodies, Monoclonal, Humanized -- administration & dosage
Antibodies, Monoclonal, Humanized -- economics
Asthma -- drug therapy
Asthma -- immunology
Eosinophilia -- drug therapy
Interleukin-5 -- immunology
United States

2. Alternative pricing models for remdesivir and other potential treatments for COVID-19

Author(s):

Whittington, Melanie D., author
Campbell, Jonathan D., author

Publication:

[Boston, Massachusetts] : Institute for Clinical and Economic Review, June 24, 2020

Subject(s):

Antiviral Agents -- economics
Coronavirus Infections -- drug therapy
Drug Costs
Models, Economic
Pandemics
Pneumonia, Viral -- drug therapy
United States

3. Digital health technologies as an adjunct to medication assisted therapy for opioid use disorder: final evidence report and meeting summary

Author(s):

Tice, Jeffrey A., author
Whittington, Melanie D., author
Fluetsch, Noemi, author
Zapata, Lorenzo Villa, author
Mendola, Nicolas D., author
Chapman, Rick M., author
Campbell, Jonathan D., author
Pearson, Steven D., author
Bradt, Pamela, author

Publication:

[Boston, Massachusetts] : Institute for Clinical and Economic Review, December 11, 2020

Subject(s):

Behavior Therapy
Digital Technology
Opiate Substitution Treatment
Opioid-Related Disorders -- therapy
United States

4. Special assessment of outpatient treatments for COVID-19: nirmatrelvir/ritonavir (Paxlovid) health-benefit price benchmark update

Author(s):

Whittington, Melanie D., author
Campbell, Jonathan D., author
Richardson, Marina, author
Nhan, Emily, author
McKenna, Avery, author
Agboola, Foluso, author
Pearson, Steven D., author

Publication:

[Boston, Massachusetts] : Institute for Clinical and Economic Review, December 20, 2022

Subject(s):

Ambulatory Care -- economics
Antiviral Agents -- economics
COVID-19 Drug Treatment
Drug Combinations
Drug Costs
Lactams
Leucine
Nitriles
Proline
Ritonavir
United States

5. JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value : final evidence report

Author(s):

Atlas, Steven J., author
Fox, Grace E., author
Agboola, Foluso, author
Campbell, Jonathan D., author
Pearson, Steven D., author
Rind, David M., author
Brouwer, Elizabeth, author
Carlson, Josh, author
Chen, Yilin, (Of University of Washington), author
Hansen, Ryan N., author

Publication:

[Boston, Massachusetts] : Institute for Clinical and Economic Review, February 27, 2023

Subject(s):

Antibodies, Monoclonal -- therapeutic use
Dermatitis, Atopic
Janus Kinase Inhibitors -- therapeutic use
United States

6. Tezepelumab for severe asthma: final report

Author(s):

Rind, David M., author
Campbell, Jonathan D., author
Herce-Hagiwara, Belén, author
Herron-Smith, Serina, author
Fluetsch, Noemi, author
Pearson, Steven D., author
McQueen, R. Brett, author
Gutierrez, Eric, (Of University of Colorado), author

Publication:

[Boston, Massachusetts] : Institute for Clinical and Economic Review, February 13, 2023

Subject(s):

Antibodies, Monoclonal, Humanized -- therapeutic use
Asthma -- drug therapy
United States

7. Gene therapies for sickle cell disease: final evidence report

Author(s):

Beaudoin, Francesca, author
Nikitin, Dmitriy, author
Campbell, Jonathan D., author
McKenna, Avery, author
Pearson, Steven D., author
Rind, David M., author
Thokala, P. (Praveen), author
Spackman, David Eldon, author

Publication:

[Boston, Massachusetts] : Institute for Clinical and Economic Review, August 21, 2023

Subject(s):

Anemia, Sickle Cell -- therapy
Genetic Therapy
United States

8. Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: effectiveness and value : final evidence report

Author(s):

Lin, Grace A., author
Whittington, Melanie D., author
Nikitin, Dmitriy, author
Agboola, Foluso, author
McKenna, Avery, author
Herron-Smith, Serina, author
Pearson, Steven D., author
Campbell, Jonathan D., author

Publication:

[Boston, Massachusetts] : Institute for Clinical and Economic Review, February 21, 2023

Subject(s):

Antibodies, Monoclonal -- therapeutic use
Multiple Sclerosis, Relapsing-Remitting -- drug therapy
Treatment Outcome
Administration, Oral
United States

9. Treatments for anemia in chronic kidney disease: effectiveness and value : final evidence report

Author(s):

Mustafa, Reem A., author
Fox, Grace, (Of Institute for Clinical and Economic Review), author
Campbell, Jonathan D., author
Agboola, Foluso, author
Pearson, Steven D., author
Rind, David M., author
Bloudek, Lisa, author
Carlson, Josh J., author

Publication:

[Boston, Massachusetts] : Institute for Clinical and Economic Review, March 5, 2021

Subject(s):

Glycine -- analogs & derivatives
Hematinics -- therapeutic use
Isoquinolines -- therapeutic use
Hypoxia-Inducible Factor-Proline Dioxygenases -- antagonists & inhibitors
Anemia, Iron-Deficiency -- drug therapy
Renal Insufficiency, Chronic -- complications
Renal Insufficiency, Chronic -- drug therapy
Treatment Outcome
United States